SCHEMBL3072275

SCHEMBL3072275

O=C1NCc2c1c1c(c3[nH]c4ccccc4c23)Cc2ccccc2-1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP3K11 Q16584 11/20 1.00
MAP3K9 P80192 10/20 1.00
PRKCA P17252 5/20 1.00
MAP3K10 Q02779 4/20 1.00
KDR P35968 4/20 1.00
PRKD3 O94806 4/20 1.00
PRKCG P05129 4/20 1.00
PRKCB P05771 4/20 1.00
PRKCH P24723 4/20 1.00
PRKCI P41743 4/20 1.00
PRKCE Q02156 4/20 1.00
PRKCQ Q04759 4/20 1.00
PRKCZ Q05513 4/20 1.00
PRKCD Q05655 4/20 1.00
PRKD1 Q15139 4/20 1.00
NTRK1 P04629 2/20 1.00
GLI1 P08151 1/20 0.66
GLI2 P10070 1/20 0.66
CDK4 P11802 1/20 0.66
CTRB1 P17538 1/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3082217 0.90 MAP3K9 (1.00) MAP3K11MAP3K9PRKCAMAP3K10KDR
SCHEMBL6629443 0.87 MAP3K9 (0.76) MAP3K11MAP3K9PRKCAMAP3K10KDR
SCHEMBL6627111 0.87 MAP3K9 (0.76) MAP3K11MAP3K9PRKCAMAP3K10KDR
SCHEMBL6628810 0.87 MAP3K11 (0.76) MAP3K11MAP3K9PRKCAMAP3K10KDR
SCHEMBL3268039 0.87 MAP3K9 (0.76) MAP3K11MAP3K9PRKCAMAP3K10KDR
SCHEMBL3268623 0.85 MAP3K9 (0.73) MAP3K11MAP3K9PRKCAMAP3K10KDR
SCHEMBL14494154 0.84 KDR (0.74) MAP3K11MAP3K9PRKCAMAP3K10KDR
SCHEMBL14494184 0.84 MAP3K9 (0.72) MAP3K11MAP3K9PRKCAMAP3K10KDR
SCHEMBL3075228 0.82 MAP3K9 (0.80) MAP3K11MAP3K9PRKCAMAP3K10KDR
SCHEMBL14494163 0.82 MAP3K9 (0.69) MAP3K11MAP3K9PRKCAMAP3K10KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8410267-B2 Regioselective reduction of fused pyrrolocarbazoles-5,7-diones TEVA SANTE (FR) 2013-04-02 US disclosed
US-8383813-B2 Fused pyrrolocarbazoles CEPHALON, INC. (US) 2013-02-26 US disclosed
US-20120004253-A1 Novel Fused Pyrrolocarbazoles CEPHALON, INC. (US) 2012-01-05 US disclosed
US-8044064-B2 Fused pyrrolocarbazoles CEPHALON, INC. (US) 2011-10-25 US disclosed
US-8044064-B2 Fused pyrrolocarbazoles CEPHALON, INC. (US) 2011-10-25 US disclosed
US-20110224436-A1 REGIOSELECTIVE REDUCTION OF FUSED PYRROLOCARBAZOLES-5,7-DIONES CEPHALON FRANCE (FR) 2011-09-15 US disclosed
US-7789610-B2 Methods for preventing/treating damage to sensory hair cells and cochlear neurons CEPHALON, INC. (US) 2010-09-07 US disclosed
US-7789610-B2 Methods for preventing/treating damage to sensory hair cells and cochlear neurons CEPHALON, INC. (US) 2010-09-07 US disclosed
US-7789610-B2 Methods for preventing/treating damage to sensory hair cells and cochlear neurons CEPHALON, INC. (US) 2010-09-07 US disclosed
US-20100152196-A1 Novel Fused Pyrrolocarbazoles CEPHALON, INC. (US) 2010-06-17 US disclosed
US-7169802-B2 Fused pyrrolocarbazoles CEPHALON, INC. (US) 2007-01-30 US disclosed
US-7169802-B2 Fused pyrrolocarbazoles CEPHALON, INC. (US) 2007-01-30 US disclosed
EP-1088823-B1 Fused pyrrolocarbazoles CEPHALON INC (US) 2004-12-29 EP disclosed
EP-1126855-A4 METHODS FOR PREVENTING/TREATING DAMAGE TO SENSORY HAIR CELLS AND COCHLEAR NEURONS CEPHALON INC (US) 2004-05-19 EP disclosed
US-6448283-B1 FUSED PYRROLOCARBAZOLES; HEARING LOSS AND LOSS OF THE SENSE OF BALANCE CEPHALON, INC. 2002-09-10 US disclosed
US-20020115706-A1 Methods for preventing/treating damage to sensory hair cells and cochlear neurons CEPHALON, INC. 2002-08-22 US disclosed
EP-0785938-B1 FUSED PYRROLOCARBAZOLES CEPHALON INC (US) 2002-01-02 EP disclosed
EP-1126855-A1 METHODS FOR PREVENTING/TREATING DAMAGE TO SENSORY HAIR CELLS AND COCHLEAR NEURONS CEPHALON, INC. (US) 2001-08-29 EP disclosed
WO-2000018407-A1 METHODS FOR PREVENTING/TREATING DAMAGE TO SENSORY HAIR CELLS AND COCHLEAR NEURONS CEPHALON, INC. (US) 2000-04-06 WO disclosed
US-5591855-A KINASE INHIBITORS, TROPHIC FACTOR-INDUCED ACTIVITY ENHANCEMENT, CELL SURVIVAL CEPHALON, INC. (US) 1997-01-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100152196-A1 Novel Fused Pyrrolocarbazoles PC, PYCR1, CYP11B2 MAP3K11 3535/4885MAP3K9 3651/4885PRKCA 2189/4885
US-20120004253-A1 Novel Fused Pyrrolocarbazoles PC, PYCR1, CYP11B2 MAP3K11 3535/4885MAP3K9 3651/4885PRKCA 2189/4885
US-20020115706-A1 Methods for preventing/treating damage to sensory hair cells and cochlear neurons GJB2, GAP43, MYOC MAP3K11 2895/4885MAP3K9 2839/4885PRKCA 1259/4885
US-20110224436-A1 REGIOSELECTIVE REDUCTION OF FUSED PYRROLOCARBAZOLES-5,7-DIONES CYP51A1, DHPS, PRMT7 MAP3K11 1596/4885MAP3K9 2177/4885PRKCA 1460/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.